- Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Investigational new drugs.
Times cited: 22
- Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012 Academic Article GET IT
- Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011 Academic Article GET IT